New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, published August 26th in the open-access journal PLOS Biology.
https://www.news-medical.net/n....ews/20250826/New-ora